Phase I clinical trial of UBX1325 yields positive data for patients with vascular eye diseaseJuly 9th 2021
According to Unity Biotechnology, its trial for the small molecule inhibitor of Bcl-xL found improvement in visual acuity and central subfield thickness observed in diabetic macular edema and wet age-related macular degeneration patients treated with UBX1325.
Oyster Point Pharma unveils preclinical study results for Enriched Tear Film Gene Therapy to target ocular surface diseasesJune 3rd 2021
According to the company, preclinical study results from a 42-day proof-of-concept in vivo study demonstrated a single, intralacrimal gland injection of an adeno-associated virus containing the NGF gene produced statistically significant increase in NGF in tear film, as compared to placebo, as early as Day 7.
Results unveiled from phase 2/3 gene therapy study for XLRPMay 14th 2021
While Biogen’s XIRIUS study did not meet its primary endpoint of demonstrating a statistically significant improvement in treated eyes, positive trends were observed across several clinically relevant prespecified secondary endpoints.
Gene therapy prompts foveal morphologic changes in LCAMay 10th 2021
Friederike Kortuem, MD, MSc, discusses how treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.
X-linked retinitis pigmentosa Phase 1/2 clinical trial provides positive 12-month dataMay 6th 2021
According to Applied Genetic Technologies Corp., groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials.
Investigators uncover improved vectors for ocular gene therapyFebruary 24th 2021
Gene therapies to mitigate the effects of mutations that cause blindness are undergoing rapid development. Investigators have found that novel gene vectors reduce the risks associated with these procedures.